Microport Biotechnology: The application for clinical trial of Theloron Capsules has been accepted.

Weixin Bio announced that the clinical trial application for the self-developed Sioroni capsule for the treatment of metastatic pancreatic ductal adenocarcinoma has obtained the "Acceptance Notice" issued by the Drug Evaluation Center of the National Medical Products Administration. The acceptance numbers are CXHL2501217 and CXHL2501219, and the acceptance date is November 6, 2025. Sioroni capsule is a novel small molecule anti-tumor drug with a new chemical structure of Class 1, which has a multi-pathway anti-tumor mechanism by inhibiting multiple kinase targets such as AuroraB, CSF1R, and VEGFR/PDGFR/c-Kit, exerting a comprehensive anti-pancreatic cancer effect.